At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more T-shirts are quintessential for any wardrobe, regardless of the season. They're a classic top on their ...

Long-sleeved T-shirts are an underrated wardrobe staple. As stylist and fashion designer Jordan Page of @veryadvanced points out, the humble long-sleeved tee can look “classier than short ...

"Each injection is painful." In the recent study, researchers explored if the diabetes and obesity drug tirzepatide(the active ingredient in Zepbound and Mounjaro) could improve CGL, as it improves ...

Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in 2023. These medications, best known by brand names like Ozempic and ...

The primary endpoint of the Phase 2 BMT-801 clinical trial is to demonstrate the safety and efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients were ...

After hours: February 7 at 7:57:05 PM EST ...

This Feature (BMJ 2025;388:q2636, doi:10.1136/bmj.q2636, published 3 February 2025) stated that the NICE guidance on tirzepatide was still in draft form. In fact ...